| Year |
Citation |
Score |
| 2022 |
Droctové L, Ciolek J, Mendre C, Chorfa A, Huerta P, Carvalho C, Gouin C, Lancien M, Stanajic-Petrovic G, Braco L, Blanchet G, Upert G, De Pauw E, Barbe P, Keck M, et al. A new Kunitz-type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor. British Journal of Pharmacology. PMID 35122240 DOI: 10.1111/bph.15814 |
0.636 |
|
| 2021 |
Hus-Citharel A, Bouby N, Corbani M, Mion J, Mendre C, Darusi J, Tomboly C, Trueba M, Serradeil-Le Gal C, Llorens-Cortes C, Guillon G. Characterization of a functional V vasopressin receptor in the male rat kidney, evidence for crosstalk between V and V receptor signaling pathways. American Journal of Physiology. Renal Physiology. PMID 34282956 DOI: 10.1152/ajprenal.00081.2021 |
0.411 |
|
| 2020 |
Droctové L, Lancien M, Tran VL, Susset M, Jego B, Theodoro F, Kessler P, Mourier G, Robin P, Diarra SS, Palea S, Flahault A, Chorfa A, Corbani M, Llorens-Cortes C, ... ... Mendre C, et al. A snake toxin as a theranostic agent for the type 2 vasopressin receptor. Theranostics. 10: 11580-11594. PMID 33052234 DOI: 10.7150/thno.47485 |
0.614 |
|
| 2019 |
Mendre C, Mouillac B. Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics. Advances in Protein Chemistry and Structural Biology. 118: 249-272. PMID 31928727 DOI: 10.1016/Bs.Apcsb.2019.07.002 |
0.775 |
|
| 2018 |
Droctové L, Ciolek J, Lancien M, Stura EA, Vera L, Floquet N, Witzgall R, Mouillac B, Mendre C, Mourier G, Servent D, Gilles N. Crystal structure and functional domains of the Mambaquaretin-1, a vasopressin type 2 receptor peptide inhibitor for kidney cysts treatment Toxicon. 149: 91-92. DOI: 10.1016/J.Toxicon.2017.12.021 |
0.644 |
|
| 2017 |
Perkovska S, Méjean C, Ayoub MA, Li J, Hemery F, Corbani M, Laguette N, Ventura MA, Orcel H, Durroux T, Mouillac B, Mendre C. V1b vasopressin receptor trafficking and signaling : role of arrestins, G proteins and Src kinase. Traffic (Copenhagen, Denmark). PMID 29044966 DOI: 10.1111/Tra.12535 |
0.765 |
|
| 2017 |
Mouillac B, Mendre C. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors. Handbook of Experimental Pharmacology. PMID 28939971 DOI: 10.1007/164_2017_50 |
0.772 |
|
| 2017 |
Ciolek J, Reinfrank H, Quinton L, Viengchareun S, Stura EA, Vera L, Sigismeau S, Mouillac B, Orcel H, Peigneur S, Tytgat J, Droctové L, Beau F, Nevoux J, Lombès M, ... ... Mendre C, et al. Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 28630289 DOI: 10.1073/Pnas.1620454114 |
0.687 |
|
| 2016 |
Ciolek J, Reinfrank H, Servent D, Mourier G, Mouillac B, Quinton L, Mendre C, Witzgall R, Gilles N. Activity of Mambaquaretin toxin on kidney disease via its interaction with vasopressin V2 receptor Toxicon. 116: 76. DOI: 10.1016/J.Toxicon.2016.01.016 |
0.669 |
|
| 2014 |
Karpenko IA, Kreder R, Valencia C, Villa P, Mendre C, Mouillac B, Mély Y, Hibert M, Bonnet D, Klymchenko AS. Red fluorescent turn-on ligands for imaging and quantifying G protein-coupled receptors in living cells. Chembiochem : a European Journal of Chemical Biology. 15: 359-63. PMID 24449564 DOI: 10.1002/Cbic.201300738 |
0.718 |
|
| 2014 |
Mouillac B, Mendre C. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies. Pharmacological Research. 83: 74-8. PMID 24239889 DOI: 10.1016/J.Phrs.2013.10.007 |
0.73 |
|
| 2012 |
Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, Sharma KS, Durand G, Pucci B, Trinquet E, Zwier JM, Deupi X, Bron P, Banères JL, Mouillac B, et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proceedings of the National Academy of Sciences of the United States of America. 109: 6733-8. PMID 22493271 DOI: 10.1073/Pnas.1201093109 |
0.719 |
|
| 2011 |
Bellot G, Pascal R, Mendre C, Urbach S, Mouillac B, Déméné H. Expression, purification and NMR characterization of the cyclic recombinant form of the third intracellular loop of the vasopressin type 2 receptor Protein Expression and Purification. 78: 131-138. PMID 21575724 DOI: 10.1016/J.Pep.2011.04.020 |
0.709 |
|
| 2010 |
Mendre C, Mouillac B. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases]. Medecine Sciences : M/S. 26: 627-35. PMID 20619166 DOI: 10.1051/Medsci/2010266-7627 |
0.608 |
|
| 2010 |
Arcemisbéhère L, Sen T, Boudier L, Balestre MN, Gaibelet G, Detouillon E, Orcel H, Mendre C, Rahmeh R, Granier S, Vivès C, Fieschi F, Damian M, Durroux T, Banères JL, et al. Leukotriene BLT2 receptor monomers activate the Gi2 GTP-binding protein more efficiently than dimers Journal of Biological Chemistry. 285: 6337-6347. PMID 20026606 DOI: 10.1074/Jbc.M109.083477 |
0.736 |
|
| 2010 |
Cottet M, Albizu L, Perkovska S, Jean-Alphonse F, Rahmeh R, Orcel H, Méjean C, Granier S, Mendre C, Mouillac B, Durroux T. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes. Current Opinion in Pharmacology. 10: 59-66. PMID 19896898 DOI: 10.1016/J.Coph.2009.10.003 |
0.753 |
|
| 2010 |
Tenenbaum J, Ayoub M, Perkovska S, Adra-Delenne A, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D. CL110 - Le syndrome d’antidiurèse inappropriée néphrogénique (NSIAD) : une pathologie récente et encore méconnue Archives De PéDiatrie. 17: 30. DOI: 10.1016/S0929-693X(10)70326-2 |
0.688 |
|
| 2009 |
Tenenbaum J, Ayoub MA, Perkovska S, Adra-Delenne AL, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D. The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation. Plos One. 4: e8383. PMID 20027297 DOI: 10.1371/Journal.Pone.0008383 |
0.782 |
|
| 2009 |
Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Méjean C, Morin D, Loison S, Bonnet D, Hibert M, Mouillac B, Mendre C. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. Journal of the American Society of Nephrology : Jasn. 20: 2190-203. PMID 19729439 DOI: 10.1681/Asn.2008121289 |
0.749 |
|
| 2009 |
Bellot G, Granier S, Bourguet W, Seyer R, Rahmeh R, Mouillac B, Pascal R, Mendre C, Déméné H. Structure of the Third Intracellular Loop of the Vasopressin V2 Receptor and Conformational Changes upon Binding to gC1qR Journal of Molecular Biology. 388: 491-507. PMID 19285506 DOI: 10.1016/J.Jmb.2009.02.065 |
0.711 |
|
| 2009 |
Orcel H, Albizu L, Perkovska S, Durroux T, Mendre C, Ansanay H, Mouillac B, Rabié A. Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane. Molecular Pharmacology. 75: 637-47. PMID 19047484 DOI: 10.1124/Mol.108.049031 |
0.774 |
|
| 2008 |
Granier S, Jean-Alphonse F, Bacqueville D, Monteil A, Pascal R, Poncet J, Guillon G, Boudier L, Arcemisbéhère L, Mouillac B, Bellot G, Déméné H, Mendre C. The multifunctional protein GC1q-R interacts specifically with the i3 loop arginine cluster of the vasopressin V2 receptor Regulatory Peptides. 148: 76-87. PMID 18358546 DOI: 10.1016/J.Regpep.2008.01.007 |
0.802 |
|
| 2006 |
Granier S, Jean-Alphonse F, Déméné H, Guillon G, Pascal R, Mendre C. Design and synthesis of cyclic and linear peptide-agarose tools for baiting interacting protein partners of GPCRs Bioorganic and Medicinal Chemistry Letters. 16: 521-524. PMID 16289816 DOI: 10.1016/J.Bmcl.2005.10.061 |
0.744 |
|
| 2004 |
Granier S, Terrillon S, Pascal R, Déméné H, Bouvier M, Guillon G, Mendre C. A cyclic peptide mimicking the third intracellular loop of the V2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein. The Journal of Biological Chemistry. 279: 50904-14. PMID 15452133 DOI: 10.1074/Jbc.M405089200 |
0.546 |
|
| 2003 |
Déméné H, Granier S, Muller D, Guillon G, Dufour MN, Delsuc MA, Hibert M, Pascal R, Mendre C. Active peptidic mimics of the second intracellular loop of the V(1A) vasopressin receptor are structurally related to the second intracellular rhodopsin loop: a combined 1H NMR and biochemical study. Biochemistry. 42: 8204-13. PMID 12846569 DOI: 10.1021/Bi027358N |
0.553 |
|
| 1997 |
Mendre C, Dufour MN, Le Roux S, Seyer R, Guillou L, Calas B, Guillon G. Synthetic rat V1a vasopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor. The Journal of Biological Chemistry. 272: 21027-36. PMID 9261104 DOI: 10.1074/jbc.272.34.21027 |
0.45 |
|
| 1996 |
Mendre C, Hamroun D, Dupoirieux L, Calas B, Chevillard C. Endothelin receptor synthetic N-terminal fragment interacts with the receptor itself. Peptides. 17: 521-6. PMID 8735982 DOI: 10.1016/0196-9781(95)02128-0 |
0.4 |
|
| 1995 |
Mezgueldi M, Mendre C, Calas B, Kassab R, Fattoum A. Characterization of the regulatory domain of gizzard calponin. Interactions of the 145-163 region with F-actin, calcium-binding proteins, and tropomyosin. The Journal of Biological Chemistry. 270: 8867-76. PMID 7721794 DOI: 10.1074/Jbc.270.15.8867 |
0.306 |
|
| 1988 |
Galas MC, Lignon MF, Rodriguez M, Mendre C, Fulcrand P, Laur J, Martinez J. Structure-activity relationship studies on cholecystokinin: analogues with partial agonist activity. The American Journal of Physiology. 254: G176-82. PMID 2450468 DOI: 10.1152/Ajpgi.1988.254.2.G176 |
0.301 |
|
| Show low-probability matches. |